ATP1A3 (middle) Polyclonal antibody

ATP1A3 (middle) Polyclonal Antibody for IF, IHC, WB, ELISA

Host / Isotype

Rabbit / IgG


Human and More (1)





Cat no : 28030-1-AP


ATP1A3, ATP1A3 (middle), DYT12, RDP, Sodium pump subunit alpha 3

Tested Applications

Positive WB detected inHeLa cells, SH-SY5Y cells, SKOV-3 cells, U-87 MG cells
Positive IHC detected inhuman prostate cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inHeLa cells

Recommended dilution

Western Blot (WB)WB : 1:5000-1:50000
Immunohistochemistry (IHC)IHC : 1:50-1:500
Immunofluorescence (IF)IF : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

28030-1-AP targets ATP1A3 (middle) in WB, IHC, IF, ELISA applications and shows reactivity with Human samples.

Tested Reactivity Human
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen ATP1A3 (middle) fusion protein Ag27705
Full Name ATPase, Na+/K+ transporting, alpha 3 polypeptide
Calculated Molecular Weight 113 kDa
Observed Molecular Weight 113 kDa
GenBank Accession NumberBC015566
Gene Symbol ATP1A3
Gene ID (NCBI) 478
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

ATP1A3 participates in the catalyticing hydrolysis of ATP and the exchanging of sodium and potassium ions across plasma membrane. The catalyticing activity mode is ATP + H2O + Na+(In) + K+(Out) = ADP + phosphate + Na+(Out) + K+(In). It has been published that the neurologic disorders rapid-onset dystonia-parkionsonism (RDP), alternating hemiplegia of childhood (ACH) and CAPOS syndrome (cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing loss) are all related with the mutation of ATP1A3. There are other reports suggest that early life epilepsy and episodic apnea revealing are potentially associated with the mutation of ATP1A3 as a result of impairment of Na+/K+ homeostasis. This antibody is generated agaist the middle region (378-580aa) of ATP1A3 and detects 113 kDa protein in SDS-PAGE.(PMID: 30097153, 20301294, 29922587)


Product Specific Protocols
WB protocol for ATP1A3 (middle) antibody 28030-1-APDownload protocol
IHC protocol for ATP1A3 (middle) antibody 28030-1-APDownload protocol
IF protocol for ATP1A3 (middle) antibody 28030-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols


humanWB, IF

Sci Adv

De novo ATP1A3 variants cause polymicrogyria.

Authors - Satoko Miyatake

Nat Commun

Homophilic ATP1A1 binding induces activin A secretion to promote EMT of tumor cells and myofibroblast activation.

Authors - Yi-Ing Chen